Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Renlo Health vs Zealthy

By GLP-1 ScorecardUpdated

Renlo HealthFactor scores not reassessed.
Site position #40

Higher score

ZealthyFactor scores not reassessed.
Site position #513

Lower score

Score comparison

Renlo Health has the higher recorded score — 79.7/100 to 46.7/100.

Renlo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.

Before you choose

Before comparing the headline prices, the Renlo Health review and the Zealthy review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Alegro Health vs Renlo Health and Science & Co vs Zealthy compare each of them with another graded program, and the list of alternatives to Renlo Health ranks the programs closest to Renlo Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the WellMedr review covers one graded close to these two, at 63.2/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRenlo Health +58
84
26
Dose & formulationRenlo Health +8
72
64
Clinical oversightRenlo Health +47
88
41
Labs & monitoringRenlo Health +5
58
53
FulfillmentRenlo Health +24
90
66
Contract termsRenlo Health +49
90
41
Renlo Health · top barZealthy · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricRenlo HealthZealthy
WeighScore79.7/10046.7/100
GradeC+C
Site position#40#513
Semaglutide$149/mo at every dose (shown against $299)$151/mo on a 3-month supply, plus a separate membership (bundle $217 first month, then $297/mo; compounded)
Tirzepatide$199/mo at every dose (shown against $399)From $216/mo, plus a separate membership (bundle $349 first month, then $449/mo; compounded)
CoverageNot publicly listed34 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Renlo Health

Site position #40 · C+

Factor scores not reassessed.

Strengths

  • The headline is the real month-to-month rate — no prepay division and no commitment behind an asterisk
  • A genuine all-in line: medication, injection supplies, provider evaluation, ongoing care, expedited shipping and unlimited care-team messaging, with no membership or consultation fees
  • Names the prescribing physician, Dr. Sean Arora, MD, and the dispensing pharmacy, VialsRX
  • Same price at every dose with a price-lock badge
  • A four-month money-back guarantee, and cancel anytime with no fee

What to consider

  • A struck-through $399 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom
  • That strikethrough comes from a stylesheet rule rather than a struck-out element, so a markup-level check would report the page clean
  • A comparison table headed "Most GLP-1 providers" quotes $270, $365 and $445 by dose while naming no provider and citing no source
  • A site-wide $50 code means the advertised figure is not the first amount charged
  • No lab protocol is published, and there is no oral or brand route
Zealthy

Site position #513 · C

Factor scores not reassessed.

FDAWarning letter issued to FitRX, LLC dba Zealthy in September 2025. See the FDA warning-letter database.

Strengths

  • Serves 34 states — meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

What to consider

  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • FDA issued FitRX, LLC dba Zealthy a warning letter in September 2025; the letter is public in FDA's warning-letter database

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard